Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Treatment for narrowing of vertebral arteries using drug-eluting stents

Official title: Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study

Run by Nanfang Hospital, Southern Medical University · NCT05644314 · Data updated 2026-11-12

This study is testing a new type of stent to see if it can help people with narrowed vertebral arteries reduce their risk of strokes and improve their brain health.

More Ischemic Stroke trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment144 (estimated)
SponsorNanfang Hospital, Southern Medical University
Academic / other
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedMay 1, 2022
Main results expectedMay 31, 2026
Study endsMay 31, 2029
Registry record updatedMarch 14, 2023
Trial IDNCT05644314 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who require a drug-eluting vertebral artery stent and can comply with the study protocols.

Probably not a fit

Patients with severe systemic diseases, uncontrolled hypertension, or those who cannot undergo dual antiplatelet therapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of a drug-eluting stent system for patients with atherosclerotic vertebral artery stenosis, which can lead to ischemic strokes. It is a prospective, multi-center, open-access, single-arm trial where participants will be monitored for clinical outcomes at 30 days, 6 months, and 12 months post-procedure, with annual follow-ups for up to three years. The study focuses on assessing the long-term efficacy of the stent in reducing the risk of stroke recurrence and improving neurological outcomes.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of stroke recurrence and improve the quality of life for patients with vertebral artery stenosis.

How similar studies have gone: Previous studies have shown that drug-eluting stents can effectively reduce restenosis rates, indicating potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years old, gender is not limited;
2. Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;
3. Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.

Exclusion Criteria:

1. Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;
2. With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;
3. Gastrointestinal disease with active bleeding;
4. Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;
5. Known contraindications to heparin, rapamycin, anesthesia, and contrast agents;
6. Life expectancy less than 12 months;
7. the investigator judged patients to be unsuitable for participation in this study.

Where it's running

  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

  • Principal investigator: Zhong Ji, PHD — Nanfang Hospital, Southern Medical University
  • Study coordinator: Zhong Ji, PHD
  • Email: jizhong22@hotmail.com
  • Phone: 020-62787664

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.